Some preclinical findings revealed that SHP2 promotes immune suppression in the tumor microenvironment; thus, the allosteric inhibition of SHP2 by RMC-4550 could induce antitumor immunity (Quintana et al., 2020). The gene discussed is PTPN11; the disease is neoplasm.